XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
Go back to XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis| Pfizer Inc. (NYSE: PFE) | Delayed: 27.91 +0.12 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.79 | 52 Week High | $37.39 | |||
| Open | $27.76 | 52 Week Low | $28.25 | |||
| Day High | $27.92 | P/E | 16.92 | |||
| Day Low | $27.57 | EPS | $1.65 | |||
| Volume | 9,955,042 | |||||
